Neurologic clinical trials - Adamas -ADS-AMT-MS303

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03436199

This is a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group study of ADS-5102 (amantadine extended release [ER] capsules) in MS patients with walking impairment. ADS-5102 will be administered once daily at bed time.

Drug

Drug: ADS-5102,137 mg, ADS-5102,274 mg, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Multiple sclerosis (MS)

Keywords

Adamas | ADS-5102 | Walking impairment | Multiple Sclerosis (MS)